Muhammad Asad

University of Chemistry and Technology, Prague

Papers

Total Citations

H-Index

About

Dr. Muhammad Asad is at the forefront of cancer nanomedicine, a field he has helped propel from its foundational roots into a new era of precision oncology. His landmark review, "Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics," has already garnered 15 citations since its 2025 publication, reflecting its immediate impact in shaping the discourse on programmable drug delivery systems. Asad’s major contribution lies in mapping the coherent evolution of the field—from passive EPR-mediated accumulation to active ligand targeting and personalized therapeutics—providing a critical roadmap for researchers and clinicians alike. His work synthesizes decades of progress since the 1995 approval of Doxil®, offering a visionary framework for next-generation cancer treatments. By articulating how smart targeting and patient-specific strategies converge, Asad has established himself as a key architect of the transition from conventional nanomedicine to truly personalized oncology. His insights are essential reading for anyone seeking to understand the trajectory of cancer therapy and the promise of nanoscale interventions in clinical practice.